Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Shi Yeen, Tiffany Ng ^a   Pathmanathan, Rajadurai ^b   Shiran, Mohd Sidik ^a   Ahmad Zaid, Fattah Azman ^a   Cheah, Yoke Kqueen ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

EGFR; HRM; Scorpion ARMS

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PRIORITY JOURNAL; RELIABILITY; TUMOR BIOPSY; BIOPSY; CHEMISTRY; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY;

SCORPIONES;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; FORMALDEHYDE; HUMANS; LUNG NEOPLASMS; MUTATION; PARAFFIN EMBEDDING; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84876095273     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-22     Document Type: Article

References (28)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Cancer Incidence in Peninsular Malaysia, 2003-2005 Kuala Lumpur: National Cancer Registry, Lim GCC, Rampal S, Halimah Y, 2008 22126556
3. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Stella GM, Luisetti M, Inghilleri S, Cemmi F, Scabini R, Zorzetto M, Pozzi E, Respir Med 2012 106 173 183 10.1016/j.rmed.2011.10.015 22104541
4. Epidermal growth factor receptor mutation-guided treatment for lung cancers: where are we now? Su Z, Thoracic Cancer 2011 2 1 6 10.1111/j.1759-7714. 2010.00035.x
5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA, N Engl J Med 2004 350 2129 2139 10.1056/NEJMoa040938 15118073 (Pubitemid 38637993)
6. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M, Science 2004 304 1497 10.1126/science. 1099314 15118125 (Pubitemid 38720929)
7. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H, PNAS 2004 101 36 13306 13311 10.1073/pnas.0405220101 15329413 (Pubitemid 39209661)
8. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, Jänne PA, Ladanyi M, Oxnard GR, Clin Cancer Res 2012 18 6 1790 1797 10.1158/1078-0432.CCR-11-2361 22190593
9. Prospective phase ii study of gefitinib for chemotherapy- naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T, J Clin Oncol 2006 24 21 3340 3346 10.1200/JCO.2005.05.4692 16785471 (Pubitemid 46638887)
10. Differential effects of gefi tinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA, J Natl Cancer Inst 2005 97 16 1185 1194 10.1093/jnci/dji238 16106023 (Pubitemid 41258224)
11. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Nomoto K, Tsuta K, Takano T, Fukui T, Yokozawa K, Sakamoto H, Yoshida T, Maeshima AM, Shibata T, Furuta K, Ohe Y, Matsuno Y, Am J Clin Pathol 2006 126 608 615 10.1309/N5PQNGW2QKMX09X7 16938658 (Pubitemid 44498512)
12. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Yasuda H, Kobayashi S, Costa DB, Lancet Oncol 2012 13 23 31 10.1016/S1470-2045(11)70129-2 21764376
13. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH, Yu CJ, Tsai MF, Shih JY, Yang PC, Oncologist 2008 13 1276 1284 10.1634/theoncologist.2008-0093 19060236
14. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, Liu CL, Chen HC, Ku YC, Chen YT, Chang YH, Chen YT, Hsi BL, Tsai SF, Huang SF, Lung Cancer 2006 53 311 322 10.1016/j.lungcan.2006.06.005 16870303 (Pubitemid 44189569)
15. Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. Marchetti A, Del Grammastro M, Filice G, Felicioni L, Rossi G, Graziano P, Sartori G, Leone A, Malatesta S, Iacono M, Guetti L, Viola P, Mucilli F, Cuccurullo F, Buttitta F, PLoS One 2012 7 7 42164 10.1371/journal.pone.0042164 22848739
16. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JSK, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JCH, J Thorac Oncol 2011 6 10 1663 1669 10.1097/JTO.0b013e318227816a 21869714
17. Establishing an EGFR mutation screening service for non-small cell lung cancer-Sample quality criteria and candidate histological predictors. Leary AF, Castro DGD, Nicholson AG, Ashley S, Wotherspoon A, O'Brien ME, Popat S, Eur J Cancer 2012 48 61 67 22036089
18. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K, Clin Can Res 2006 12 13 3915 3921 10.1158/1078-0432.CCR-05-2324 (Pubitemid 44078075)
19. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M, Chest 2007 131 6 1628 1634 10.1378/chest.06-1673 17565015 (Pubitemid 46981613)
20. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A, BMC Cancer 2008 8 142 10.1186/1471-2407-8-142 18495026 (Pubitemid 351785125)
21. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A, BMC Cancer 2006 6 295 10.1186/1471-2407-6-295 17184525 (Pubitemid 46178886)
22. Diagnostic method validation: High resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene. Norambuena PA, Copeland JA, Křenková P, Štambergová A, Macek M Jr, Clin Biochem 2009 42 12 1308 1316 10.1016/j.clinbiochem.2009.04.015 19427845
23. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF, JNCI 2005 97 5 339 346 10.1093/jnci/dji055 15741570 (Pubitemid 40425952)
24. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y, J Clin Oncol 2005 23 11 2513 2520 10.1200/JCO.2005.00.992 15738541 (Pubitemid 47050841)
25. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T, J Clin Oncol 2005 23 28 6829 6837 10.1200/JCO.2005.01.0793 15998907
26. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. John T, Liu G, Tsao MS, Oncogene 2009 28 14 S23 19680292
27. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Tam IYS, Leung ELH, Tin VPC, Chua DTT, Sihoe ADL, Cheng LC, Chung LP, Wong MP, Mol Cancer Ther 2009 8 8 2142 2151 10.1158/1535-7163.MCT-08-1219 19671738
28. The measurement of observer agreement for categorical data. Landis JR, Koch GG, Biometrics 1977 33 1 159 174 10.2307/2529310 843571 (Pubitemid 8054849)